Clinical trial
3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic…
NCT00064051 · Vion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00064051 |
|---|---|
| Title | 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer |
| Official title | A Phase II Study of Triapine in Combination With Gemcitabine in Patients With Pancreatic Cancer |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, triapine |
| Start date | Jan 1, 2003 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2008 |
| First posted | Jul 9, 2003 |
| Last update posted | Aug 2, 2013 |
| Countries | Belgium, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: